• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Brammah Judd increased direct ownership by 9% to 2,963,928 units

    5/3/21 6:05:09 AM ET
    $HCCC
    Get the next $HCCC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Brammah Judd

    (Last) (First) (Middle)
    C/O VISION HYDROGEN CORPORATION
    95 CHRISTOPHER COLUMBUS DR, 16TH FLOOR

    (Street)
    JERSEY CITY NJ 07302

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    VISION HYDROGEN Corp [ VIHD ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/28/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.0001 per share 04/28/2021 S 250,000 A $0.2 2,963,928 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ JUDD BRAMMAH 05/03/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HCCC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HCCC

    DatePrice TargetRatingAnalyst
    1/24/2022$18.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $HCCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann initiated coverage on Healthcare Capital with a new price target

    Ladenburg Thalmann initiated coverage of Healthcare Capital with a rating of Buy and set a new price target of $18.00

    1/24/22 7:16:23 AM ET
    $HCCC

    $HCCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Tau Medical and Healthcare Capital Corp. Announce Completion of Business Combination

    JERUSALEM and WILMINGTON, Del., March 7, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. ("Alpha Tau"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, and Healthcare Capital Corp. (NASDAQ:HCCC) ("HCCC"), a special purpose acquisition company, announced today the successful closing of the previously announced business combination (the "Business Combination"). The combined company will continue to be led by Alpha Tau's existing management team. Alpha Tau's ordinary shares and warrants are expected to begin trading on Tuesday, March 8, 2022, on Nasdaq under the ticker symbols "DRTS" and "DRTSW," respectively. The transaction, and the various proposals giving effect ther

    3/7/22 8:32:00 AM ET
    $HCCC

    Healthcare Capital Corp. and Alpha Tau Medical Ltd. Announce Stockholder Approval of the Business Combination

    NEW YORK and JERUSALEM, ISRAEL , Feb. 22, 2022 (GLOBE NEWSWIRE) --  Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") and Alpha Tau Medical Ltd. ("Alpha Tau"), an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors, today announced that in its special meeting held on February 18, 2022, HCCC's stockholders voted to approve the previously announced proposed business combination (the "Business Combination") of HCCC and Alpha Tau. Approximately 94.57% of the votes cast at the meeting, representing approximately 65.64% of HCCC's outstanding shares as of the record date, voted

    2/22/22 7:30:00 AM ET
    $HCCC

    Healthcare Capital Corp. Announces Adjournment of Special Meeting of Stockholders

    NEW YORK, NY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Healthcare Capital Corp. (NASDAQ:HCCC, HCCCW, and HCCCU))) ("HCCC") today announced that on February 18, 2022, it convened and then adjourned, without conducting any other business, its special meeting of stockholders (the "Special Meeting"). The Special Meeting has been adjourned until February 18, 2022 at 4:00p.m. Eastern Time (the "Adjournment"). The Special Meeting is being held to approve the business combination (the "Business Combination") with Alpha Tau Medical Ltd. ("Alpha Tau") and related proposals, as described in HCCC's definitive proxy statement filed with the Securities and Exchange Commission ("SEC") on January 14, 2022. The

    2/18/22 11:38:11 AM ET
    $HCCC

    $HCCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Milch David Mark converted options into 1,923,925 shares and disposed of 1,923,925 shares

    4 - Healthcare Capital Corp/DE (0001822935) (Issuer)

    3/9/22 9:30:25 PM ET
    $HCCC

    SEC Form 4: Doyle Michael was granted 2,500 units of Common Stock

    4 - VISION HYDROGEN Corp (0001676580) (Issuer)

    5/14/21 1:08:25 PM ET
    $HCCC

    SEC Form 4: BENTON CHARLES F was granted 2,500 units of Common Stock

    4 - VISION HYDROGEN Corp (0001676580) (Issuer)

    5/14/21 1:06:11 PM ET
    $HCCC

    $HCCC
    SEC Filings

    View All

    SEC Form 25-NSE filed by Healthcare Capital Corp.

    25-NSE - Healthcare Capital Corp/DE (0001822935) (Subject)

    3/7/22 4:22:12 PM ET
    $HCCC

    Healthcare Capital Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

    8-K - Healthcare Capital Corp/DE (0001822935) (Filer)

    2/22/22 4:05:34 PM ET
    $HCCC

    SEC Form 425 filed by Healthcare Capital Corp.

    425 - Healthcare Capital Corp/DE (0001822935) (Subject)

    2/18/22 1:10:14 PM ET
    $HCCC

    $HCCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Healthcare Capital Corp. (Amendment)

    SC 13G/A - Healthcare Capital Corp/DE (0001822935) (Subject)

    3/9/22 11:16:23 AM ET
    $HCCC

    SEC Form SC 13G filed by Healthcare Capital Corp.

    SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)

    2/18/22 4:13:27 PM ET
    $HCCC

    SEC Form SC 13G filed by Healthcare Capital Corp.

    SC 13G - Healthcare Capital Corp/DE (0001822935) (Subject)

    2/14/22 4:01:26 PM ET
    $HCCC